Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 1, 2008, Pages 13-21

  Tirado Conde, Gema ^a   Lara, Beatriz ^a   Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Alpha 1 antitrypsin deficiency; augmentation therapy; emphysema; management

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; TRYPSONE; UNCLASSIFIED DRUG; ZEMAIRA;

ABSENCE OF SIDE EFFECTS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANAPHYLAXIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DELTA AGENT HEPATITIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; GENE MUTATION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LIVER INJURY; LUNG EMPHYSEMA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRION DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STREPTOCOCCUS INFECTION;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; EMPHYSEMA; HUMANS;

EID: 68749090208     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465807088159     Document Type: Article

References (41)

1. Alpha-1-Antitrypsin Deficiency Registry Study Group. (1998) Survival and FEV1 decline
2. in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 158: 49–59.
3. ATS/ERS(American Thoracic Society/European Respiratory Society) Statement: (2003) standards for the diagnosis and management of individuals with alpha-antitrypsin deficiency. Am J Resp Clin Care Med 168: 818–900.
4. Barker, A.F., Siemsen, F., Pasley, D., D'Silva, R., Buist, A.S. (1994) Replacement therapy for hereditary alpha-1-antitrypsin deficiency. A program for long-term administration. Chest 105: 1406–1410.
5. Bals, R., Koczulla, R., Kokte, V., Andress, J., Blackert, K. and Vogelmeier, C. (2007) Identification on individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir, Med 101: 1708–1714.
6. Blanco, I., de Serres, F.J., Fernández-Bustillo, E., Lara, B., Miravitlles, M. (2006) Estimates of the prevalence of alpha-1-antitrypsin deficiency PI*S and PI*Z alleles and the numbers at risk in European countries. Eur Respir J 27: 77–84.
7. Campos, M.A., Wanner, A., Zhang, G., Sandhaus, R.A. (2005) Trends in the diagnosis of symptomatic patients with alpha-1 antitrypsin deficiency between 1968 and 2003. Chest 128: 1179–1186.
8. Cassina, P.C., Teschler, H., Konietzko, N., Theegarten, D., Stamatis, G. (1998) Two-year results after lung volume reduction surgery in alpha-1-antitrypsin deficiency versus smoker's emphysema. Eur Respir J 12: 1028–1032.
9. Corda, L., Bertella, E., Pini, L., Pezzini, A., Medicina, D., Boni, E. et al. (2006) Diagnostic flow chart for targeted detection of alpha-1-antitrypsin deficiency. Respir Med 100: 463–470.
10. De la Roza, C., Rodríguez-Frías, F., Lara, B., Vidal, R., Jardí, R., Miravitlles, M. (2005) Results of a case-detection programme for alpha-1-antitrypsin deficiency in COPD patients. Eur Respir J 26: 616–622.
11. De la Roza, C., Lara, B., Vilà, S., Miravitlles, M. (2006) Alpha-1-antitrypsin deficiency: situation in Spain and development of a screening program. Arch Bronconeumol 42: 290–298.
12. DeMeo, D.L., Sandhaus, R.A., Barker, A.F., Brantly, M.L., Eden, E., McElvany, N.G. et al. (2007) Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax 62: 805–812.
13. Dirksen, A., Dijkman, J.H., Madsen, F., Stoel, B., Hutchison, D.C., Ulrik, C.S. et al. (1999) A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160: 1468–1472.
14. Hill, A.T., Campbell, E.J., Bayley, D.L., Hill, S.L., Stockley, R.A. (1999) Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 160: 1968–1975.
15. Hubbard, R.C., Sellers, S., Czerski, D., Stephens, L., Crystal, R.G. (1988) Biochemical efficacy and safety of monthly augmentation therapy for alpha-1-antitrypsin deficiency. JAMA 260: 1259–1264.
16. Lara, B., de la Roza, C., Vilà, S., Vidal, R., Miravitlles, M. (2007) Development and results of the Spanish registry of patients with alpha-1 antitrypsin deficiency. Int J COPD 2: 393–398.
17. Lieberman, J. (2000) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 118: 1480–1485.
18. Luisetti, M., Miravitlles, M., Stockley, R.A. (2002) Alpha-1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genova, Italy), 2001. Eur Respir J 20: 1050–1056.
19. Luisetti, M., Massi, G., Massobrio, M., Guarraci, P., Menchicchi, M. (1999) A national program for detection of alpha1-antitrypsin deficiency in Italy. Respir Med 93: 169–172.
20. Memoranda WHO. (1997) Alpha1-antitrypsin deficiency: memorandum from a WHO meeting. Bull WHO 75: 397–415.
21. Miravitlles, M., Vidal, R., Torrella, M., Bofill, J.M., Cotrina, M., de Gracia, J. (1994) Evaluación del tratamiento sustitutivo del enfisema por déficit de alfa-1-antitripsina. Arch Bronconeumol 30: 479–484.
22. Miravitlles, M., Vidal, R., Barros-Tizón, J.C., Bustamante, A., España, P.P., Casas, F. et al. (1998) Usefulness of a national Registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir Med 92: 1181–1187.
23. Miravitlles, M., de Gracia, J., Rodrigo, M.J., Cruz, M.J., Vendrell, M., Vidal, R. et al. (1999a) Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha-1-antitrypsin deficiency with and without bronchiectasis. Chest 116: 946–952.
24. Miravitlles, M., Vidal, R., Barros-Tizón, J.C., Bustamante, A., España, P.P., Casas, F. et al. (1999b) Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registro Nacional. Arch Bronconeumol 35: 446–454.
25. Miravitlles, M. (2005) Tratamiento de la enfermedad pulmonar obstructiva crónica. Med Clin (Barc) 125: 65–74.
26. Needham, M., Stockley, R.A. (2005) Exacerbations in alpha-1-antitrypsin deficiency. Eur Respir J 25: 992–1000.
27. Schmidt, E.W., Rasche, B., Ulmer,W.T., Konietzko, N., Becker, M., Fallise, J.P. et al. (1988) Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease. Am J Med 84 Suppl 6A: 63–69.
28. Schwaiblmair, M., Vogelmeier, C., Fruhmann, G. (1997) Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency’ three-year follow-up. Respiration 64: 10–15.
29. Seersholm, N., Wencker, M., Banik, N., Viskum, K., Dirksen, A., Kok-Jensen, A. et al. (1997) Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 10: 2260–2263.
30. Soy, D., de la Roza, C., Lara, B., Esquinas, C., Torres, A., Miravitlles, M. (2006) Alpha-1-antirypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 61: 1059–1064.
31. Stockley, R.A., Bayley, D.L., Unsal, I., Dowson, L.J. (2002) The effect of augmentation therapy on bronchial inflammation in alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 165: 1494–1498.
32. Stockley, R.A., Luisetti, M., Miravitlles, M., Piitulainen, E., Fernandez, P. and on behalf of the Alpha One International Registry (A.I.R.) group. (2007) Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. Eur Respir J 29: 582–586.
33. Stoller, J.K., Rouhani, F., Brantly, M., Shahin, S., Dweik, R.A., Stocks, J.M. et al. (2002) Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 122: 66–74.
34. Stoller, J.K., Fallat, R., Schluchter, M.D., O'Brien, R.G., Connor, J.T., Gross, N. et al. (2003) Augmentation therapy with alpha-1-antitrypsin: patterns of use and adverse events. Chest 123: 1425–1434.
35. Stoller, J.K., Aboussonan, L.S. (2004) Alpha-1-antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 59: 708–712.
36. Stoller, J.K., Sandhaus, R.A., Turino, G., Dickson, R., Rodgers, K., Strange, C. (2005) Delay in diagnosis of alpha-1-antitrypsin deficiency: a continuing problem. Chest 128: 1989–1994.
37. Vidal, R., Drobnic, M.E., Sala, F., Padulles, N., Montoro, J.B., Jardí, R. et al. (2006a) Farmacocinética de la alfa-1-antitripsina utilizada en el tratamiento sustitutivo del enfisema congénito grave. Arch Bronconeumol 42: 553–556.
38. Vidal, R., Blanco, I., Casas, F., Jardí, R., Miravitlles, M. (2006b) y Comité del Registro Nacional de Pacientes con Déficit de Alfa-1-antitripsina. Normativa SEPAR: Diagnóstico y tratamiento del déficit de alfa-1-antitripsina. Arch Bronconeumol 42: 645–659.
39. Wencker, M., Fuhrmann, B., Banik, N., Konietzko, N., for the Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. (2001) Longitudinal follow-up of patients with alpha-1-protease inhibitor deficiency before and during therapy with alpha-1-protease inhibitor. Chest 119: 737–744.
40. Wencker, M., Marx, A., Konietzko, N., Schaefer, B., Campbell, E.J. (2002) Screening for alpha1-Pi deficiency in patients with lung diseases. Eur Respir J 20: 319–324.
41. Wewers, M.D., Casolaro, M.A., Sellers, S.E., Swayze, S.C., McPhaul, K.M., Wittes, J.T. et al. (1987) Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N Engl J Med 316: 1055–1062.